Abstract
Chemotherapy (CT) and endocrine therapy (ET) are used sequentially in systemic management of ER+ve HER2-negative early breast cancer, leading to a delay in the initiation of ET. There is little randomized data to assess the benefits/harms of concurrent chemo-endocrine therapy (CET) using aromatase inhibitors (AI). We examined neoadjuvant CT with the addition of letrozole (plus goserelin in pre-/peri-menopausal women) versus CT alone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
